Showing posts with label tobacco. Show all posts
Showing posts with label tobacco. Show all posts

Wednesday, December 14, 2011

Scientific Standards for Studies on Modified Risk Tobacco Products

Dec. 14, 2011.WASHINGTON. A new Institute of Medicine report specifies the types of research that the Food and Drug Administration should require before allowing tobacco companies to sell or advertise ‘modified risk’ tobacco products as being capable of reducing the health risks of tobacco use.  While modified risk tobacco products could be one part of a comprehensive strategy to lower tobacco-related death and disease in the U.S., especially among tobacco users who are unable or unwilling to quit entirely, little is currently known about the products’ health effects and whether they pose less risk than traditional tobacco products. Examples of modified risk tobacco products may include e-cigarettes and tobacco lozenges.

Companies and other sponsors developing modified risk tobacco products should consider using FDA-approved independent third parties to oversee health and safety research on their products, adds the report, which was completed to fulfill a congressional mandate. Independent oversight would ensure that the data submitted to FDA are reliable and credible, and it could help re-engage the mainstream scientific community in research.  Because of the tobacco industry’s well-documented history of improper conduct, many institutions and scientists currently refuse to conduct or publish research supported by the tobacco industry.
“Right now there’s a shortage of scientific evidence on the health effects of modified risk tobacco products, and the tobacco industry currently lacks the trustworthiness, expertise, and infrastructure to produce it,” said Jane Henney, chair of the committee that wrote the report, and professor of medicine and public health sciences at the University of Cincinnati.  “Having trusted third parties oversee the conduct of research could help re-engage scientists and enable generation of credible research data on the health effects of these products.”

The Family Smoking Prevention and Tobacco Control Act of 2009 requires that modified-risk tobacco products undergo a pre-market approval process similar to drugs and devices.  According to the act, a company that wants to market a lower risk tobacco product in the U.S. must offer scientific proof to FDA that the marketing of the product will not only reduce harm to individual users, but also benefit the health of the population as a whole.  The act also directed FDA to consult with IOM on how scientific studies of modified risk tobacco products should be designed and conducted.

The IOM’s report says that the studies should examine all of the areas needed to forecast and monitor a proposed product’s impact on public health, including its composition and addiction potential; the amount of human exposure to harmful components; perceptions about the product’s effects and likelihood of addiction; and effects on human health.  Studies should be generalizable to the whole population and should also include populations of special relevance, including current and former smokers, beginning smokers, adolescents, and populations at high risk for tobacco use.

While studies submitted to FDA to demonstrate products’ safety are usually conducted or sponsored by the companies themselves, the tobacco industry at present lacks the capacity and expertise to conduct such research, the report says.  The industry’s history of improper manipulation of data undermined the credibility of its research and left it isolated from the mainstream scientific community.  Many major universities have policies against acceptance of tobacco funding, for example, and many high-impact scientific and medical journals will not accept manuscripts supported by the tobacco industry.

Using independent, FDA-approved third parties to conduct, provide oversight of, and distribute funding for research could distance the influence and reputation of the tobacco industry from the scientists who are researching their products.  Examples of third-party partnerships between industry and government include the Health Effects Institute and the Reagan-Udall Foundation. No similar organization currently exists for the tobacco industry.

Making data publicly available will also build public trust and will allow for independent analysis of data and methods, the report says.  FDA should require sponsors of modified risk tobacco products to place all data generated during a product’s development and marketing in a public repository selected by the agency.  

FDA should also require that studies offered in support of an application to market modified risk tobacco products conform to established standards of good research governance, including appropriately qualified investigators, transparency, independent institutional review board or ethical review, and adherence to federal regulations that ensure the protection of human participants in biomedical research.

The study was sponsored by the Food and Drug Administration.  Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public.  The National Academy of Sciences, National Academy of Engineering, Institute of Medicine, and National Research Council make up the National Academies. 


z

Thursday, November 10, 2011

FDA acts to protect children from illegal tobacco sales

The U.S. Food and Drug Administration sent Warning Letters to more than 1,200 retailers, the majority of which respond to violations relating to selling tobacco to minors, as part of its ongoing effort to reduce tobacco use among children.

While most retail establishments inspected by the FDA have been found to be in compliance with the law, some retailers are still selling cigarettes and smokeless tobacco to minors. Warning Letters may be followed by civil money penalties if retailers continue to violate the law.

“It should worry every parent that 20 percent of U.S. high school students smoke cigarettes,” said FDA Commissioner Margaret A. Hamburg. “President Obama and the FDA are committed to preventing children from smoking. For many young people, that first cigarette or use of smokeless tobacco will lead to a lifetime of addiction, and for many, serious disease. More than 80 percent of adult smokers begin smoking before 18 years of age. Retailers are vital partners in the FDA’s efforts to prevent tobacco use among kids.”

President Obama signed the Family Smoking Prevention and Tobacco Control Act that gives the FDA authority to regulate tobacco products to prevent use by minors and reduce the impact on public health. One of the law’s provisions permits the FDA to contract with states and territories to conduct compliance check inspections of tobacco retailers. In 2011, the FDA awarded compliance contracts totaling more than $24 million to 38 states, including the District of Columbia, supporting the creation of at least 266 jobs.

As of today, FDA-commissioned officials have conducted more than 27,500 compliance checks. Retail inspections focus on sale and distribution restrictions, including:
  • age and ID verification
  • requirements for labeling and advertising of smokeless tobacco products
  • restrictions on the sale of single cigarettes
  • a ban on certain candy and fruit-flavored cigarettes
  • prohibited self service displays and vending machines
Full inspection results are posted on the FDA website. The site lists all retailer Warning Letters and a monthly list of inspected establishments where no violations were observed.

“Through this program, we are exercising the authority Congress and the President gave to FDA to enforce the youth access and advertising regulations that took effect in June 2010,” said Lawrence R. Deyton, director of FDA’s Center for Tobacco Products. “While we applaud the efforts made by many retail establishments to protect our kids, the fact that our nation’s youth can walk into 1,200 retail locations and still obtain access to these deadly products is 1,200 too many.”

FDA also began inspecting U.S. tobacco product manufacturers in October 2011. This is the first time tobacco product manufacturing facilities have ever been inspected by a federal public health agency. Inspections of tobacco product manufacturing facilities are required to be conducted at least once every two years.

For more information:

Wednesday, November 2, 2011

Intellectual property council talks health, tobacco packaging and enforcement

WTO members assessed the system for helping poorer countries import cheaper medicines, debated whether an Australian bill on plain packaging for cigarettes will hurt poor farmers, and scrutinized a new agreement among a group of countries on stronger intellectual property enforcement, when they met as the TRIPS Council on 24-25 October 2011.

On the “Paragraph 6 system”, which helps countries import cheaper generic medicines, they also agreed that the deadline should be extended for another two years for countries to accept an amendment to the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, as the number of countries doing so gradually rises. The WTO General Council is expected to approve the decision when it meets in December.

But they delayed a decision on a long-standing, controversial and legally complex question, which could be taken up at the 15–17 December 2011 Ministerial Conference in Geneva. This about the possibility of countries challenging each other in the WTO dispute settlement procedure on intellectual property issues even if the TRIPS agreement has not been violated, and only an expected right has been thwarted: “non-violation” cases in TRIPS.

The possibility of filing non-violation cases in intellectual property was ruled out temporarily in the TRIPS Agreement. This “moratorium” on cases of this kind has so far been extended from one ministerial conference to the next. Switzerland and the US continue to oppose extending the moratorium but they are willing to continue consulting. Most members oppose non-violation cases and want the moratorium extended or the possibility scrapped completely.

The council reviewed China’s implementation of its intellectual property obligations for the last time under Beijing’s 2001 membership agreement, with some praise for the efforts the country has made in protecting intellectual property but also concerns about the amount of counterfeiting and piracy.

The two-day meeting also spent some time on a trio of issues related to biodiversity, biopiracy and patenting life forms (see www.wto.org/tripsbio), with the discussion largely following that of previous meetings.

And it examined various aspects of technical assistance, and developed countries’ incentives for their companies and institutions to transfer technology to least developed countries.
SOME DETAILS
First, a decision:
TRIPS and public health: the Par.6 system and the annual review
Full explanations: www.wto.org/tripshealth
See also: the
2010 review, and follow-up

Background. This was the annual review of how the “Par.6 system” is working. The system removes an intellectual property obstacle that would have prevented countries from using compulsory licences to manufacture generic medicines exclusively for export to countries unable to make them themselves. It refers to paragraph 6 of the 2001 Doha Declaration on TRIPS and Public Health.

The General Council first agreed to remove the obstacle through a 2003 “waiver”, a legal means allowing WTO members not to comply with an obligation or provision in a WTO agreement. Two years later it agreed to an almost identical amendment to the TRIPS Agreement, which is still pending.
Accepting the amendment
More information here

The TRIPS Council agreed to extend the deadline for accepting the 2005 amendment for another two years until 31 December 2013, the third extension. This is needed in order to allow the number of accepting members to reach the two-thirds required for the amendment to take effect.

The extension will be put to the General Council’s December meeting, which is expected to approve it — both the General Council and the TRIPS Council consist of all 153 WTO members.

The number of countries accepting the amendment is rising steadily. Argentina, Indonesia and New Zealand accepted it just before this meeting, and Turkey, Costa Rica and Rwanda said they will do so soon. Rwanda has already benefited from imports under the system.

Ecuador and Cuba said they are not ready to accept the amendment — Ecuador, because it considers the system not to be working; Cuba because it thinks the TRIPS Council still needs to study the situation more. The EU said this position is unfair to potential importing countries.
The WTO Secretariat repeated the clarification that accepting the amendment is completely independent from revising a country’s own laws and regulations to implement the Par.6 system. When enough countries have accepted the amendment, they will be allowing their fellow-members to use it; when they revise their own laws and regulations, they allow themselves to use it.
This clarification has encouraged at least one country — New Zealand — to accept the amendment before its law is modified. A number of others had already made that choice.
The review
The review lasted just over two hours, considerably shorter than the previous year’s review. This was partly because chairperson González urged members not to repeat what they had said in the October 2010 review and March 2011 follow-up. He had supplied them with detailed references to paragraphs in the minutes of these meetings (documents IP/C/M/64 and IP/C/M/65).
It was organized under six headings:
  • members’ experience in using or considering using the system (only used once for Canadian exports to Rwanda)
  • implementing the system in domestic law and regulations
  • accepting the amendment
  • capacity building on the Par.6 system and related flexibilities
  • alternatives to the system for access to medicines, including procurement and other means
  • next steps and recommendations
The comments were broadly on these themes:
Update on Canada’s revised law. Canada said the Private Member’s Bill C-393 for amending Canada’s Access to Medicines Regime (CAMR), which is the law for Canada to export under compulsory licensing (ie, the Par.6 system), died before it could be passed because Parliament was dissolved for the May general election. The government opposed the bill and therefore has no plans to revive it, Canada said. It could not say whether any member of Parliament will propose a new bill.
Is the Par.6 system working? Should there be a workshop? Some developing countries continued to argue that since the system has only been used once, it is too complicated to be effective. Some others questioned whether it is working and said they need more information. They repeated the call for a workshop open to all members with other participants also invited such as non-governmental organizations, and research-based and generic pharmaceutical companies.
Some asked the EU and US about their practices related to a provision of the TRIPS Agreement — Art.31(k) — on actions for dealing with anti-competitive practices, They referred to court cases which they said waived the restrictions on compulsory licences for export, allowing the entire production to be exported and therefore serving as an alternative to the Par.6 system.
Some developed countries continued to argue that the number of times the system has been used is not a good measure of its effectiveness because it is only one among a wide range of policies for making medicines more available and affordable.
Compulsory licensing under the Par.6 system can also be used as a bargaining chip to lower prices. When it is used it is working and when it is not used it could still be working, one delegation said.
These developed countries also remarked that potential importers under the Par.6 system have not described their experience in using or considering using the system. This was among their reasons for arguing that work should continue among members within the TRIPS Council, some adding that delegations could seek information from outside organizations and introduce that into the council’s discussions.
The one country that has imported under the Par.6 system, Rwanda, did speak. It said it fully supports the system and is about to accept the TRIPS amendment.
Australia’s plain packaging bill for tobacco products
The bill, first discussed in the last meeting, has passed the lower house and is now in the Senate, Australia reported. It is part Australia’s anti-smoking campaign. (See also this Australian government web page, which includes images of samples of the proposed packaging.)
Ukraine (represented by Economy Vice Minister Valery Pjatnitsky), and a number of developing countries (Dominican Rep, Mexico, Nigeria, Cuba, Nicaragua, Honduras, El Salvador, Zimbabwe) repeated their concern that the law will violate Australia’s obligations under the TRIPS Agreement by preventing cigarette and cigar companies from using their trademarks, ultimately hurting their poor farmers. Some argued that the plain packaging will make counterfeiting easier, and some said it will cut costs and lower prices, stimulating demand rather than inhibiting it.
Chile, China, Switzerland, India and the EU asserted countries’ right to use flexibilities in the TRIPS Agreement for public health purposes, including tobacco control, sought more information and some of them urged Australia to ensure that its measures do not conflict with the agreement. Brazil stressed all countries’ right to adopt measures to protect public health, which it consider an important general principle for the relationship between intellectual property protection and health.
Uruguay, New Zealand and Norway supported Australia, which described how serious a problem smoking is and assured members that the policy has been studied carefully to ensure it does not violate TRIPS provisions and that it will be effective in reducing smoking. The World Health Organization described the serious global picture and said plain packaging is part of its Framework Convention on Tobacco Control.
Anti-Counterfeiting Trade Agreement (ACTA)
The ACTA text is in document IP/C/W/563.
Many participants in the ACTA negotiations (Australia, Canada, the EU, Rep. Korea, Japan, New Zealand, Singapore, Switzerland and the US) informed the membership about the agreement, which eight of them signed on 1 October 2011 and the EU, Mexico and Switzerland are expected to sign soon.
They described ACTA as a means of strengthening the enforcement of intellectual property rights without altering the obligations of the TRIPS Agreement. The Doha Declaration on TRIPS and Public Health, which makes health a priority, is upheld (in the preamble), they said, and generic medicines in transit or traded across borders will not be affected because the agreement excludes patents from actions at the border (footnote 6 of Article 13).
India, Angola, Ecuador, Brazil, China, Chile, Venezuela and Zimbabwe repeated a number of concerns raised in previous meetings (June and October 2010, including whether access to medicines would be impeded, or pressure would increase on countries to protect intellectual property to a higher standard than required in the WTO (the ACTA countries said they would not), and the implications for the WTO system of discussing an agreement negotiated outside the WTO.
The question of discussing intellectual property enforcement routinely in the TRIPS Council has been controversial from time to time. Some developed countries wanted to discuss it because they considered counterfeiting and piracy to be a serious problem; developing countries resisted, fearing that this would target them and be used to argue for new standards more stringent than those in TRIPS. The ACTA countries said this background of opposition to work on enforcement in the WTO was one reason why they negotiated the agreement outside the WTO. Then some developing countries raised the ACTA negotiations in some meetings, one of the complaints being a lack of information.
In this meeting India said it appreciated the information and the briefings that had been given by the ACTA countries, although it still has concerns.
China’s final transitional review
This was the TRIPS Council’s final transitional review of how China is implementing its intellectual property rights obligations under the TRIPS Agreement and its 2001 membership deal. The reviews are a unique requirement in China’s the membership agreement for a range of WTO subjects including intellectual property, annually for the first eight years and once more after 10 years.
Japan (document IP/C/W/556), the US, EU, Rep. Korea and Canada praised China for the efforts it has put into protecting intellectual property rights, the information it has supplied to the committee, in some cases the bilateral cooperation that has taken place and the campaigns on protection.
But they and their companies remain seriously concerned about counterfeiting and piracy, particularly digital, hi-tech and brandname products. They commented on a range of issues, such as the threshold set to determine whether a case is serious enough to justify prosecution and other aspects of the enforcement process. Some were also concerned about legislation involving compulsory technology transfer.
Mexico’s particular concern was about the protection of tequila and mescal as geographical indications, partly linked to a sanitary and phytosanitary regulation setting a maximum alcohol content which Mexico said is too low for some types of the spirits. It also complained about a Chinese beer (“Cerono”) mimicking Mexico’s Corona brand.
India wanted China to explain a law prevent patenting on “scientific discoveries”. Nigeria said it is concerned about exports of substandard and counterfeit products.
China circulated a document (IP/C/W/564) before the meeting, outlining latest developments in revising its copyright, trademark and patent laws, enforcement, and other intellectual property issues. In the meeting it explained these at length in reply to members’ questions.
It concluded by thanking members for cooperation over the 10 years of the review and pledged to continue to work with them bilaterally and in the WTO. China said its government had shown the political will to implement and enforce intellectual property protection and highlighted the Chinese population’s increasing awareness about the issue.
Chairperson: Ambassador Federico A González (Paraguay)
Next meetings
TRIPS Council (regular) meetings (could change):
2012
Tuesday-Wednesday 28–29 February
Tuesday-Wednesday 5–6 June
Tuesday-Wednesday 6–7 November